<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>Pfizer Inc — News on 6ix</title>
    <link>https://6ix.com/company/pfizer-inc</link>
    <description>Latest news and press releases for Pfizer Inc on 6ix.</description>
    <language>en-us</language>
    <lastBuildDate>Wed, 29 Apr 2026 10:45:00 GMT</lastBuildDate>
    <generator>6ix RSS</generator>
    <atom:link href="https://6ix.com/rss/company/pfizer-inc" rel="self" type="application/rss+xml" />
    <image>
      <url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo6835ab4a78dffbe2df10d85e.webp</url>
      <title>Pfizer Inc</title>
      <link>https://6ix.com/company/pfizer-inc</link>
    </image>
    <item>
      <title>Pfizer’s ELREXFIO Significantly Improves Progression-Free Survival for Double-Class Exposed Patients with Relapsed or Refractory Multiple Myeloma</title>
      <link>https://6ix.com/company/pfizer-inc/news/pfizers-elrexfio-significantly-improves-progression-free-survival-for-double-class-exposed-patients-with-relapsed-or-refractory-multiple-myeloma</link>
      <guid isPermaLink="true">https://6ix.com/company/pfizer-inc/news/pfizers-elrexfio-significantly-improves-progression-free-survival-for-double-class-exposed-patients-with-relapsed-or-refractory-multiple-myeloma</guid>
      <pubDate>Wed, 29 Apr 2026 10:45:00 GMT</pubDate>
      <description>NEW YORK, April 29, 2026--Pfizer Inc. (NYSE: PFE) today announced positive topline results from the Phase 3 MagnetisMM-5 study evaluating ELREXFIO® (elranatamab) as monotherapy in adults with relapsed or refractory multiple myeloma (RRMM) who received at least one prior line of treatment. The study demonstrated a statistically significant and clinically meaningful improvement in the primary endpoint of progression‑free survival (PFS), as assessed by blinded independent central review (BICR), ver</description>
    </item>
    <item>
      <title>Pfizer Reaches Three Settlement Agreements for VYNDAMAX</title>
      <link>https://6ix.com/company/pfizer-inc/news/pfizer-reaches-three-settlement-agreements-for-vyndamax</link>
      <guid isPermaLink="true">https://6ix.com/company/pfizer-inc/news/pfizer-reaches-three-settlement-agreements-for-vyndamax</guid>
      <pubDate>Tue, 28 Apr 2026 14:17:00 GMT</pubDate>
      <description>NEW YORK, April 28, 2026--Pfizer Inc. (NYSE: PFE) today announced that it has entered into settlement agreements with generic drug manufacturers Dexcel Pharma, Hikma Pharmaceuticals and Cipla Ltd, regarding lawsuits filed in the U.S. District Court for the District of Delaware for infringement of patents relating to VYNDAMAX® (tafamidis), a treatment for cardiomyopathy transthyretin-mediated amyloidosis (ATTR-CM). These settlements extend the effective U.S. patent expiry date for VYNDAMAX to Jun</description>
    </item>
    <item>
      <title>Germany Anemia Treatment Market Forecast and Company Analysis Report 2026-2034 Featuring Akebia Therapeutics, GSK, Vertex, Pfizer, Sanofi, Takeda, Novartis, Johnson &amp; Johnson, Roche, Biocon Biologics</title>
      <link>https://6ix.com/company/pfizer-inc/news/germany-anemia-treatment-market-forecast-and-company-analysis-report-2026-2034-featuring-akebia-therapeutics-gsk-vertex-pfizer-sanofi-takeda-novartis-johnson-and-johnson-roche-biocon-biologics</link>
      <guid isPermaLink="true">https://6ix.com/company/pfizer-inc/news/germany-anemia-treatment-market-forecast-and-company-analysis-report-2026-2034-featuring-akebia-therapeutics-gsk-vertex-pfizer-sanofi-takeda-novartis-johnson-and-johnson-roche-biocon-biologics</guid>
      <pubDate>Fri, 24 Apr 2026 13:04:00 GMT</pubDate>
      <description>The Germany Anemia Treatment Market is set to reach USD 1.05 billion by 2034, growing at a CAGR of 6.84% from USD 581.344 million in 2025. This growth is driven by an aging population, increased iron-deficiency cases, and the adoption of modern intravenous iron therapies, supported by robust healthcare reimbursement frameworks and extensive screening programs. Key metropolitan areas, including Berlin, Munich, Frankfurt, and Hamburg, are at the forefront, leveraging strong healthcare infrastructu</description>
    </item>
    <item>
      <title>Pfizer Declares Second-Quarter 2026 Dividend</title>
      <link>https://6ix.com/company/pfizer-inc/news/pfizer-declares-second-quarter-2026-dividend</link>
      <guid isPermaLink="true">https://6ix.com/company/pfizer-inc/news/pfizer-declares-second-quarter-2026-dividend</guid>
      <pubDate>Wed, 22 Apr 2026 20:45:00 GMT</pubDate>
      <description>NEW YORK, April 22, 2026--Pfizer Inc. (NYSE: PFE) today announced that its board of directors declared a $0.43 second-quarter 2026 dividend on the company’s common stock, payable June 12, 2026, to holders of the Common Stock of record at the close of business on May 8, 2026. The second-quarter 2026 cash dividend will be the 350th consecutive quarterly dividend paid by Pfizer.</description>
    </item>
    <item>
      <title>Drug Delivery Devices Market Insights, Competitive Landscape, and Forecast Report 2025-2032 - Growing Use of Biologics and Biosimilars, Technological Advancements, and Active Product Developments</title>
      <link>https://6ix.com/company/pfizer-inc/news/drug-delivery-devices-market-insights-competitive-landscape-and-forecast-report-2025-2032-growing-use-of-biologics-and-biosimilars-technological-advancements-and-active-product-developments</link>
      <guid isPermaLink="true">https://6ix.com/company/pfizer-inc/news/drug-delivery-devices-market-insights-competitive-landscape-and-forecast-report-2025-2032-growing-use-of-biologics-and-biosimilars-technological-advancements-and-active-product-developments</guid>
      <pubDate>Wed, 22 Apr 2026 09:08:00 GMT</pubDate>
      <description>The drug delivery devices market offers opportunities in self-administration, home healthcare, and biologics due to rising chronic diseases. North America dominates this growing market with advanced infrastructure and R&amp;D support. Key players include Pfizer, Johnson &amp; Johnson, and AstraZeneca, driving technological developments.Dublin, April 22, 2026 (GLOBE NEWSWIRE) -- The &quot;Drug Delivery Devices - Market Insights, Competitive Landscape, and Market Forecast - 2032&quot; has been added to ResearchAndM</description>
    </item>
    <item>
      <title>Pfizer Showcases Oncology Innovation and Next-Generation Pipeline at ASCO 2026</title>
      <link>https://6ix.com/company/pfizer-inc/news/pfizer-showcases-oncology-innovation-and-next-generation-pipeline-at-asco-2026</link>
      <guid isPermaLink="true">https://6ix.com/company/pfizer-inc/news/pfizer-showcases-oncology-innovation-and-next-generation-pipeline-at-asco-2026</guid>
      <pubDate>Tue, 21 Apr 2026 15:51:00 GMT</pubDate>
      <description>NEW YORK, April 21, 2026--Pfizer Inc. (NYSE: PFE) will present new data across its diverse, industry-leading Oncology pipeline and portfolio at the American Society of Clinical Oncology (ASCO) Annual Meeting, May 29 – June 2, 2026, in Chicago. Data from more than 40 company-sponsored, investigator-sponsored and collaborative research abstracts, including three late-breaking sessions and eight oral and rapid oral presentations, will be shared. These data highlight Pfizer’s leadership in establish</description>
    </item>
    <item>
      <title>U.S. FDA Grants Priority Review to sBLA for PADCEV™ + Keytruda® as Perioperative Treatment for Muscle-Invasive Bladder Cancer Regardless of Cisplatin Eligibility</title>
      <link>https://6ix.com/company/pfizer-inc/news/us-fda-grants-priority-review-to-sbla-for-padcevtm-keytrudar-as-perioperative-treatment-for-muscle-invasive-bladder-cancer-regardless-of-cisplatin-eligibility</link>
      <guid isPermaLink="true">https://6ix.com/company/pfizer-inc/news/us-fda-grants-priority-review-to-sbla-for-padcevtm-keytrudar-as-perioperative-treatment-for-muscle-invasive-bladder-cancer-regardless-of-cisplatin-eligibility</guid>
      <pubDate>Mon, 20 Apr 2026 10:45:00 GMT</pubDate>
      <description>Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, &quot;Astellas&quot;) and Pfizer Inc. (NYSE: PFE) announced that the U.S. Food and Drug Administration (FDA) accepted for Priority Review a supplemental Biologics License Application (sBLA) for perioperative (before and after surgery) PADCEV™ (enfortumab vedotin-ejfv), a Nectin-4 directed antibody-drug conjugate, in combination with the PD-1 inhibitor Keytruda® (pembrolizumab) or Keytruda QLEX™ (pembrolizumab and berahyaluronidase alfa-pmp</description>
    </item>
    <item>
      <title>Pfizer Invites Shareholders to View and Listen to Webcast of April 23 Virtual 2026 Annual Meeting of Shareholders</title>
      <link>https://6ix.com/company/pfizer-inc/news/pfizer-invites-shareholders-to-view-and-listen-to-webcast-of-april-23-virtual-2026-annual-meeting-of-shareholders</link>
      <guid isPermaLink="true">https://6ix.com/company/pfizer-inc/news/pfizer-invites-shareholders-to-view-and-listen-to-webcast-of-april-23-virtual-2026-annual-meeting-of-shareholders</guid>
      <pubDate>Thu, 09 Apr 2026 14:00:00 GMT</pubDate>
      <description>NEW YORK, April 09, 2026--Pfizer Inc. (NYSE: PFE) announced today that its shareholders and the general public are invited to access its virtual 2026 Annual Meeting of Shareholders on Thursday, April 23, 2026, at 9:00 a.m. EDT.</description>
    </item>
    <item>
      <title>Telix Strengthens Board with Additional Director Appointments</title>
      <link>https://6ix.com/company/pfizer-inc/news/telix-strengthens-board-with-additional-director-appointments-2</link>
      <guid isPermaLink="true">https://6ix.com/company/pfizer-inc/news/telix-strengthens-board-with-additional-director-appointments-2</guid>
      <pubDate>Wed, 08 Apr 2026 22:58:00 GMT</pubDate>
      <description>Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, &quot;Telix&quot;) today announces two additional Non-Executive Director (NED) appointments, effective May 11, 2026[1], as part of Board expansion and succession planning:</description>
    </item>
    <item>
      <title>Pfizer Invites Public to View and Listen to Webcast of May 5 Conference Call with Analysts</title>
      <link>https://6ix.com/company/pfizer-inc/news/pfizer-invites-public-to-view-and-listen-to-webcast-of-may-5-conference-call-with-analysts</link>
      <guid isPermaLink="true">https://6ix.com/company/pfizer-inc/news/pfizer-invites-public-to-view-and-listen-to-webcast-of-may-5-conference-call-with-analysts</guid>
      <pubDate>Tue, 24 Mar 2026 14:00:00 GMT</pubDate>
      <description>NEW YORK, March 24, 2026--Pfizer Inc. (NYSE: PFE) invites investors and the general public to view and listen to a webcast of a conference call with investment analysts at 10:00 a.m. EDT on Tuesday, May 5, 2026. The purpose of the call is to provide an update on Pfizer’s results, as reflected in the company’s First Quarter 2026 Performance Report, to be issued that morning.</description>
    </item>
    <item>
      <title>Pfizer and Valneva Announce Lyme Disease Vaccine Candidate Demonstrates Strong Efficacy in Phase 3 VALOR Trial</title>
      <link>https://6ix.com/company/pfizer-inc/news/pfizer-and-valneva-announce-lyme-disease-vaccine-candidate-demonstrates-strong-efficacy-in-phase-3-valor-trial-1</link>
      <guid isPermaLink="true">https://6ix.com/company/pfizer-inc/news/pfizer-and-valneva-announce-lyme-disease-vaccine-candidate-demonstrates-strong-efficacy-in-phase-3-valor-trial-1</guid>
      <pubDate>Mon, 23 Mar 2026 10:45:00 GMT</pubDate>
      <description>NEW YORK &amp; LYON, France, March 23, 2026--Pfizer Inc. (NYSE: PFE) and Valneva SE (Nasdaq: VALN; Euronext Paris: VLA) today announced topline results from the Phase 3 VALOR &quot;Vaccine Against Lyme for Outdoor Recreationists&quot; clinical trial (NCT05477524) of its investigational 6-valent OspA-based Lyme disease vaccine candidate PF-07307405 (LB6V, formerly known as VLA15) demonstrating:</description>
    </item>
    <item>
      <title>Pfizer Recommends Shareholders Reject the Mini-Tender Offer by Tutanota LLC</title>
      <link>https://6ix.com/company/pfizer-inc/news/pfizer-recommends-shareholders-reject-the-mini-tender-offer-by-tutanota-llc</link>
      <guid isPermaLink="true">https://6ix.com/company/pfizer-inc/news/pfizer-recommends-shareholders-reject-the-mini-tender-offer-by-tutanota-llc</guid>
      <pubDate>Fri, 20 Mar 2026 20:30:00 GMT</pubDate>
      <description>NEW YORK, March 20, 2026--Pfizer Inc. (NYSE: PFE) today announced that it has received notice of an unsolicited mini-tender offer by Tutanota LLC (&quot;Tutanota&quot;) to purchase up to 1 million shares of Pfizer common stock at a price of $32.00 per share in cash. The offer price of $32.00 per share is conditioned on, among other things, the closing price per share of Pfizer common stock exceeding $32.00 per share on the last trading day before the offer expires. This means that unless this condition is</description>
    </item>
    <item>
      <title>TALZENNA Plus XTANDI Significantly Improves Radiographic Progression-Free Survival in Metastatic Prostate Cancer</title>
      <link>https://6ix.com/company/pfizer-inc/news/talzenna-plus-xtandi-significantly-improves-radiographic-progression-free-survival-in-metastatic-prostate-cancer</link>
      <guid isPermaLink="true">https://6ix.com/company/pfizer-inc/news/talzenna-plus-xtandi-significantly-improves-radiographic-progression-free-survival-in-metastatic-prostate-cancer</guid>
      <pubDate>Thu, 19 Mar 2026 10:45:00 GMT</pubDate>
      <description>NEW YORK, March 19, 2026--Pfizer Inc. (NYSE: PFE) today announced positive topline results from the Phase 3 TALAPRO-3 study of TALZENNA® (talazoparib), an oral poly ADP-ribose polymerase (PARP) inhibitor, in combination with XTANDI® (enzalutamide), an androgen receptor pathway inhibitor (ARPI), in people with homologous recombination repair (HRR) gene-mutated metastatic castration-sensitive prostate cancer (mCSPC), also known as metastatic hormone-sensitive prostate cancer (mHSPC).</description>
    </item>
    <item>
      <title>Pfizer Announces Positive Topline Phase 2 Results for Next-Generation CDK4 Inhibitor, Atirmociclib, in Second-Line Metastatic Breast Cancer</title>
      <link>https://6ix.com/company/pfizer-inc/news/pfizer-announces-positive-topline-phase-2-results-for-next-generation-cdk4-inhibitor-atirmociclib-in-second-line-metastatic-breast-cancer</link>
      <guid isPermaLink="true">https://6ix.com/company/pfizer-inc/news/pfizer-announces-positive-topline-phase-2-results-for-next-generation-cdk4-inhibitor-atirmociclib-in-second-line-metastatic-breast-cancer</guid>
      <pubDate>Tue, 17 Mar 2026 10:45:00 GMT</pubDate>
      <description>NEW YORK, March 17, 2026--Pfizer Inc. (NYSE: PFE) today announced positive topline results from the randomized Phase 2 FOURLIGHT-1 study evaluating atirmociclib in combination with fulvestrant, versus fulvestrant or everolimus plus exemestane, in people with hormone receptor (HR)-positive, human epidermal growth factor receptor 2-negative (HER2-) advanced or metastatic breast cancer (MBC) who had received prior cyclin-dependent kinase (CDK) 4/6 inhibitor-based treatment. The study met its primar</description>
    </item>
    <item>
      <title>Ngenla (somatrogon: Pfizer) Market Research Report 2026: Epidemiology, Pipeline Analysis, Trends, Strategies, and Forecasts, 2020-2025, 2025-2030F, 2035F</title>
      <link>https://6ix.com/company/pfizer-inc/news/ngenla-somatrogon-pfizer-market-research-report-2026-epidemiology-pipeline-analysis-trends-strategies-and-forecasts-2020-2025-2025-2030f-2035f</link>
      <guid isPermaLink="true">https://6ix.com/company/pfizer-inc/news/ngenla-somatrogon-pfizer-market-research-report-2026-epidemiology-pipeline-analysis-trends-strategies-and-forecasts-2020-2025-2025-2030f-2035f</guid>
      <pubDate>Fri, 13 Mar 2026 09:13:00 GMT</pubDate>
      <description>Key opportunities in the market include the rising demand for long-acting growth hormone therapies, expanding biologics manufacturing, and improved patient adherence. Asia-Pacific presents the fastest growth potential, with personalized endocrine care and localized production offering strategic advantages.Dublin, March 13, 2026 (GLOBE NEWSWIRE) -- The &quot;Ngenla Market Report 2026: Epidemiology, Pipeline Analysis, Market Insights &amp; Forecasts&quot; has been added to ResearchAndMarkets.com&apos;s offering. The</description>
    </item>
    <item>
      <title>Pfizer’s Phase 2 Study of Trispecific Antibody Positive in Moderate to Severe Atopic Dermatitis</title>
      <link>https://6ix.com/company/pfizer-inc/news/pfizers-phase-2-study-of-trispecific-antibody-positive-in-moderate-to-severe-atopic-dermatitis</link>
      <guid isPermaLink="true">https://6ix.com/company/pfizer-inc/news/pfizers-phase-2-study-of-trispecific-antibody-positive-in-moderate-to-severe-atopic-dermatitis</guid>
      <pubDate>Mon, 09 Mar 2026 10:45:00 GMT</pubDate>
      <description>NEW YORK, March 09, 2026--Pfizer Inc. (NYSE: PFE) today announced positive topline results from a Phase 2 study investigating tilrekimig (PF-07275315) in adults with moderate to severe atopic dermatitis. The study met its primary efficacy endpoint, demonstrating a statistically significant increase in the percentage of participants achieving EASI-75* (≥ 75% reduction in the Eczema Area and Severity Index) at Week 16, compared to placebo. In Stage 2 of the study, which evaluated monthly dosing re</description>
    </item>
    <item>
      <title>PADCEV™ + Keytruda® Cuts Risk of Recurrence or Death by Nearly 50% in Cisplatin-Eligible Muscle-Invasive Bladder Cancer</title>
      <link>https://6ix.com/company/pfizer-inc/news/padcevtm-keytrudar-cuts-risk-of-recurrence-or-death-by-nearly-50percent-in-cisplatin-eligible-muscle-invasive-bladder-cancer</link>
      <guid isPermaLink="true">https://6ix.com/company/pfizer-inc/news/padcevtm-keytrudar-cuts-risk-of-recurrence-or-death-by-nearly-50percent-in-cisplatin-eligible-muscle-invasive-bladder-cancer</guid>
      <pubDate>Fri, 27 Feb 2026 15:00:00 GMT</pubDate>
      <description>NEW YORK &amp; TOKYO, February 27, 2026--Pfizer Inc. (NYSE: PFE) and Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, &quot;Astellas&quot;) today announced positive results from the Phase 3 EV-304 clinical trial (also known as KEYNOTE-B15) for PADCEVTM (enfortumab vedotin), a Nectin-4 directed antibody-drug conjugate, in combination with Keytruda® (pembrolizumab), a PD-1 inhibitor, in patients with muscle-invasive bladder cancer (MIBC) eligible for cisplatin-based chemotherapy. Perioperative</description>
    </item>
    <item>
      <title>Novavax Reports Fourth Quarter and Full Year 2025 Financial Results and Operational Highlights</title>
      <link>https://6ix.com/company/pfizer-inc/news/novavax-reports-fourth-quarter-and-full-year-2025-financial-results-and-operational-highlights-1</link>
      <guid isPermaLink="true">https://6ix.com/company/pfizer-inc/news/novavax-reports-fourth-quarter-and-full-year-2025-financial-results-and-operational-highlights-1</guid>
      <pubDate>Thu, 26 Feb 2026 13:00:00 GMT</pubDate>
      <description>Novavax, Inc. (Nasdaq: NVAX) today announced its financial results and operational highlights for the fourth quarter and year ended December 31, 2025.</description>
    </item>
    <item>
      <title>U.S. FDA Grants Full Approval to Pfizer’s BRAFTOVI Combination Regimen in First-Line Metastatic Colorectal Cancer</title>
      <link>https://6ix.com/company/pfizer-inc/news/us-fda-grants-full-approval-to-pfizers-braftovi-combination-regimen-in-first-line-metastatic-colorectal-cancer</link>
      <guid isPermaLink="true">https://6ix.com/company/pfizer-inc/news/us-fda-grants-full-approval-to-pfizers-braftovi-combination-regimen-in-first-line-metastatic-colorectal-cancer</guid>
      <pubDate>Tue, 24 Feb 2026 19:29:00 GMT</pubDate>
      <description>NEW YORK, February 24, 2026--Pfizer Inc. (NYSE: PFE) today announced that the U.S. Food and Drug Administration (FDA) has granted full approval to BRAFTOVI® (encorafenib) in combination with cetuximab (marketed as ERBITUX®) and fluorouracil-based chemotherapy for the treatment of adult patients with metastatic colorectal cancer (mCRC) with a BRAF V600E mutation based on results from the global Phase 3 BREAKWATER trial (NCT04607421).</description>
    </item>
    <item>
      <title>Sciwind Biosciences Partners with Pfizer China to Commercialize its Biased GLP-1 in China</title>
      <link>https://6ix.com/company/pfizer-inc/news/sciwind-biosciences-partners-with-pfizer-china-to-commercialize-its-biased-glp-1-in-china</link>
      <guid isPermaLink="true">https://6ix.com/company/pfizer-inc/news/sciwind-biosciences-partners-with-pfizer-china-to-commercialize-its-biased-glp-1-in-china</guid>
      <pubDate>Tue, 24 Feb 2026 05:22:00 GMT</pubDate>
      <description>Hangzhou Sciwind Biosciences Co., Ltd. (&quot;Sciwind Biosciences&quot;) today announced a strategic commercialization collaboration with Pfizer China for Ecnoglutide injection (Ecnoglutide), a new–generation cAMP–biased GLP–1 receptor agonist. Under the agreement, Pfizer will obtain exclusive commercialization rights for the product in Mainland China, marking an important first step to advance Pfizer&apos;s global strategy in the metabolic field in China. Sciwind Biosciences will remain the Marketing Authoriz</description>
    </item>
  </channel>
</rss>